Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density.

Veldhuis-Vlug AG, Oei L, Souverein PC, Tanck MW, Rivadeneira F, Zillikens MC, Kamphuisen PW, Maitland-van der Zee AH, de Groot MC, Hofman A, Uitterlinden AG, Fliers E, de Boer A, Bisschop PH.

Osteoporos Int. 2015 Jul;26(7):2019-27. doi: 10.1007/s00198-015-3087-0. Epub 2015 Apr 25.

2.

Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice.

Motyl KJ, DeMambro VE, Barlow D, Olshan D, Nagano K, Baron R, Rosen CJ, Houseknecht KL.

Endocrinology. 2015 Jul;156(7):2374-83. doi: 10.1210/en.2015-1099. Epub 2015 Apr 8.

3.

Low dose of propranolol does not affect rat osteotomy healing and callus strength.

Smitham P, Crossfield L, Hughes G, Goodship A, Blunn G, Chenu C.

J Orthop Res. 2014 Jul;32(7):887-93. doi: 10.1002/jor.22619. Epub 2014 Apr 7.

4.

New insights into the physiology of bone regulation: the role of neurohormones.

Zofková I, Matucha P.

Physiol Res. 2014;63(4):421-7. Epub 2014 Apr 3. Review.

5.

Dysfunction of inflammation-resolving pathways is associated with exaggerated postoperative cognitive decline in a rat model of the metabolic syndrome.

Su X, Feng X, Terrando N, Yan Y, Chawla A, Koch LG, Britton SL, Matthay MA, Maze M.

Mol Med. 2013 Feb 8;18:1481-90. doi: 10.2119/molmed.2012.00351.

6.

Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor.

Hanyu R, Wehbi VL, Hayata T, Moriya S, Feinstein TN, Ezura Y, Nagao M, Saita Y, Hemmi H, Notomi T, Nakamoto T, Schipani E, Takeda S, Kaneko K, Kurosawa H, Karsenty G, Kronenberg HM, Vilardaga JP, Noda M.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7433-8. doi: 10.1073/pnas.1109036109. Epub 2012 Apr 25.

7.

α(1) adrenergic receptor agonist, phenylephrine, actively contracts early rat rib fracture callus ex vivo.

McDonald SJ, Dooley PC, McDonald AC, Djouma E, Schuijers JA, Ward AR, Grills BL.

J Orthop Res. 2011 May;29(5):740-5. doi: 10.1002/jor.21302. Epub 2010 Dec 23.

8.

The genetics of heterotopic ossification: insight into the bone remodeling pathway.

Mitchell EJ, Canter J, Norris P, Jenkins J, Morris J.

J Orthop Trauma. 2010 Sep;24(9):530-3. doi: 10.1097/BOT.0b013e3181ed147b.

PMID:
20736788
9.

Interference by adrenaline with chondrogenic differentiation through suppression of gene transactivation mediated by Sox9 family members.

Takarada T, Hojo H, Iemata M, Sahara K, Kodama A, Nakamura N, Hinoi E, Yoneda Y.

Bone. 2009 Sep;45(3):568-78. doi: 10.1016/j.bone.2009.05.004. Epub 2009 May 13.

PMID:
19446054
10.

Beta2-adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms.

Aitken SJ, Landao-Bassonga E, Ralston SH, Idris AI.

Arch Biochem Biophys. 2009 Feb;482(1-2):96-103. doi: 10.1016/j.abb.2008.11.012. Epub 2008 Nov 21.

PMID:
19059194
11.

Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis.

Bonnet N, Pierroz DD, Ferrari SL.

J Musculoskelet Neuronal Interact. 2008 Apr-Jun;8(2):94-104. Review.

12.

The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling.

Tam J, Trembovler V, Di Marzo V, Petrosino S, Leo G, Alexandrovich A, Regev E, Casap N, Shteyer A, Ledent C, Karsak M, Zimmer A, Mechoulam R, Yirmiya R, Shohami E, Bab I.

FASEB J. 2008 Jan;22(1):285-94. Epub 2007 Aug 17.

PMID:
17704191
13.

The hypothalamic control of bone mass, implication for the treatment of osteoporosis.

Karsenty G, Ducy P.

Ann Endocrinol (Paris). 2006 Apr;67(2):123. No abstract available.

PMID:
16639361

Supplemental Content

Loading ...
Support Center